Evidence map›Paper›PMID 18364705›Full record

ReviewNature clinical practice. Endocrinology & metabolism2008

Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.

Andrea Dunaif

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature clinical practice. Endocrinology & metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 7 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02491333 phase3completedstarted 2015, after this paper: background citation

The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial

Ran2015Enrolled342Registered outcomes12Posted comparisons0ConditionsInsulin Resistance, Polycystic Ovary SyndromeArmsMetformin, placebo metformin, sham acupuncture, true acupuncture
PMID 21950959PMID 12243370PMID 11602624PMID 9165656PMID 21121941PMID 22878886PMID 12900694PMID 15833138PMID 16684838PMID 16791967PMID 19420954PMID 19494176other papers from this trial
Open the trial in the graph
NCT05952882 phase3unknown statusstarted 2023, after this paper: background citation

Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility

Ran2023Enrolled188Registered outcomes60Posted comparisons0ConditionsInfertility, Female, Obesity, Polycystic Ovary SyndromeArmsLiraglutide + metformin, Metformin
PMID 28681988PMID 19056992PMID 31229399PMID 29703793PMID 19841045PMID 31733195PMID 24362411PMID 14688154PMID 17980364PMID 18068166PMID 22767467PMID 24151290other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 7 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Effect ofJournal of traditional and complementary medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Andrea DunaifDivision of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, 303 E Chicago Avenue, Tarry 15-709, Chicago, IL 60611, USA. a-dunaif@northwestern.edu
Northwestern University · US

Funding

Phenoytypes of polycystic ovary syndrome (PCOS)U54HD034449 · VIRGINIA COMMONWEALTH UNIVERSITY · 1997 to 2005
$8.4M
INSULIN ACTION IN THE POLYCYSTIC OVARY SYNDROMER01DK040605 · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · 1989 to 1997
–
NICHD NIH HHS U54 HD034449
6 · The paper itself

Abstract

The recognition that insulin resistance has a pivotal role in the pathogenesis of polycystic ovary syndrome (PCOS) revolutionized our understanding of this complex disorder. PCOS causes major metabolic and reproductive morbidities, including substantially increased risk for type 2 diabetes mellitus and the metabolic syndrome. Insulin-sensitizing drugs (ISDs) ameliorate reproductive abnormalities, restore ovulation and regular menses, increase pregnancy rates and reduce androgenic symptoms in affected women with PCOS. Accordingly, ISDs, specifically metformin, have been widely adopted as therapy for this condition. A recent, large, randomized, multicenter, clinical trial that assessed live-birth rates rather than surrogate end points suggested that metformin alone is inferior to clomiphene citrate in treating infertility associated with PCOS. There is, furthermore, no evidence to support the use of metformin during pregnancy to prevent spontaneous abortions or gestational diabetes mellitus in women with PCOS. Renewed safety concerns about thiazolidinediones followed recent studies that reported increased cardiovascular morbidity with these agents. These concerns might preclude thiazolidinedione use in otherwise healthy women with PCOS. Finally, although ISDs improve insulin action and cardiovascular disease risk, there is no evidence that they provide long-term health benefits in PCOS. This article discusses the role of ISDs in PCOS in light of these new data.

Indexed as

ClomipheneFemaleFertility Agents, FemaleHumansHyperandrogenismInfertilityInsulin ResistanceMetforminPolycystic Ovary SyndromeRandomized Controlled Trials as TopicThiazolidinedionesClomipheneFertility Agents, FemaleMetforminThiazolidinediones

Identifiers

PMID18364705
OpenAlexW2030444886

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.